[New immunomodulators in treatment of Graves'ophtalmopathy].

Ann Endocrinol (Paris)

Service d'Endocrinologie, Diabète, Maladie de la nutrition, Médecine Interne, CHU Rennes, Hôpital Sud, 16, boulevard de Bulgarie, 35000 Rennes.

Published: September 2008

Treatment of severe Graves'ophtalmopathy (GO) is a complex therapeutic challenge and spite any efforts, about one third of patients are disappointed with the outcome of treatment. Intravenous glucocorticoids (GCIV), orbital radiotherapy, or the combination of both are most frequently used for their immunosuppressive effects. The anti-CD 20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophtalmopathy (TAO). A preliminary study in nine patients with TAO treated with RTX and twenty patients treated with GCIV was reported by Salvi and al. All patients attained peripheral B-cell depletion after the first RTX infusion. At the end of follow-up, clinical activity score values decreased more significantly compared with GCIV. Proptosis and the degree of inflammation decrease significantly in response to RTX. Relapse of active TAO are not observed in patients treated with RTX but occurred in 10 % of those treated with GCIV. If these results are confirmed in large controlled studies, RTX may represent a useful therapeutic tool in patients with active TAO.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0003-4266(08)73965-9DOI Listing

Publication Analysis

Top Keywords

b-cell depletion
8
treated rtx
8
patients treated
8
treated gciv
8
active tao
8
patients
6
rtx
6
[new immunomodulators
4
immunomodulators treatment
4
treatment graves'ophtalmopathy]
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!